当前位置: 首页 » 论文全文
←返回首页
期刊信息:
《药学服务与研究》2018年, 第18卷, 第6期, 第401-405页
标题:
糖尿病肾病的生物治疗及研究进展
DOI:
10.5428/pcar20180601
作者:
1. 沈义兰(第二军医大学长海医院肾内科 上海 200433 medulla12@163.com)
2. 丁涛(第二军医大学长海医院肾内科 上海 200433 )
3. 梅小斌(第二军医大学长海医院肾内科 上海 200433 meixiaobin168@163.com)
摘要:
摘要  糖尿病肾病(diabetic nephropathy,DN)是终末期肾脏病的主要病因之一,且与心血管发病率、病死率升高密切相关。目前DN的治疗方法主要包括严格控制血糖、降低血压、使用肾素-血管紧张素-醛固酮系统阻断剂减少尿蛋白。然而这些只是对症治疗,目前还未发现专门针对DN的有效治疗方法。本文阐述了一些与DN发病机制相关的生物分子如胰高血糖素样肽-1(GLP-1)、整合素αVβ3、内皮素A(ETA)、趋化因子受体2(CCR2)等,并探讨了这些分子在DN发病机制中的作用及其临床研究进展。
欢迎阅读《药学服务与研究》!您是该文第 227 位读者!
若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式 沈义兰,丁涛,梅小斌. 糖尿病肾病的生物治疗及研究进展[J]. 药学服务与研究. 2018; 18(6): 401-405.
英文著录格式 SHEN YiLan,DING Tao,MEI XiaoBin. Advances in biotherapy of diabetic nephropathy[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(6): 401-405.
参考文献:
1. Bjornstad P,Cherney D,Maahs D M.Early diabetic nephropathy in type 1 diabetes: new insights[J].Curr Opin Endocrinol Diabetes Obes,2014,21(4):279-286.
2. Villar E,Remontet L,Labeeuw M,et al.Effect of age,gender,and diabetes on excess death in end-stage renal failure[J].J Am Soc Nephrol,2007,18(7):2125-2134.
3. Schrijvers B F,De Vriese A S,Flyvbjerg A.From hyperglycemia to diabetic kidney disease:the role of metabolic,hemodynamic,intracellular factors and growth factors/cytokines[J].Endocr Rev,2004,25(6):971-1010.
4. Yu S M,Bonventre J V.Acute kidney injury and progression of diabetic kindey disease[J].Adv Chronic Kidney Dis,2018,25(2):166-180.
5. CHEN JianChun,CHEN JianKang,Harris R C.EGF receptor deletion in podocytes attenuates diabetic nephropathy[J].J Am Soc Nephrol,2015,26(5):1115-1125.
6. Sutariya B,Jhonsa D,Saraf M N.TGF-β:the connecting link between nephropathy and fibrosis[J].Immunopharmacol Immunotoxicol,2016,38(1):39-49.
7. Wilson P G,Thompson J C,Yoder M H,et al.Prevention of renal apoB retention is protective against diabetic nephropathy: role of TGF-β inhibition[J].J Lipid Res,2017,58(12):2264-2274.
8. Voelker J,Berg P H,Sheetz M,et al.Anti-TGF-β1 antibody therapy in patients with diabetic nephropathy[J].J Am Soc Nephrol,2017,28(3):953-962.
9. Pozzi A,Zent R.Integrins in kidney disease[J].J Am Soc Nephrol,2013,24(7):1034-1039.
10. Yoon S,Gingras D,Bendayan M.Alterations of vitronectin and its receptor αv integrin in the rat renal glomerular wall during diabetes[J].Am J Kidney Dis,2001,38(6):1298-1306.
11. Maile L A,Busby W H,Gollahon K A,et al.Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs[J].Endocrinology,2014,155(12):4665-4675.
12. ZHOU XiaoYan,ZHANG Ji,Haimbach R,et al.An integrin antagonist (MK-0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model[J].Pharmacol Res Perspect,2017,5(5):1-14.
13. Tanaka T,Higashijima Y,Wada T,et al.The potential for renoprotection with incretin-based drugs[J].Kidney Int,2014,86(4):701-711.
14. Fujita H,Morii T,Fujishima H,et al.The protective roles of GLP-1R signaling in diabetic nephropathy:possible mechanism and therapeutic potential[J].Kidney Int,2014,85(3):579-589.
15. Mann J F E,rsted D D,Brown-Frandsen K,et al.Liraglutide and renal outcomes in type 2 diabetes[J].N Engl J Med,2017,377(9):839-848.
16. de Zeeuw D,Coll B,Andress D,et al.The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy[J].J Am Soc Nephrol,2014,25(5):1083-1093.
17. Scholten D J,Canals M,Maussang D,et al.Pharmacological modulation of chemokine receptor function[J].Br J Pharmacol,2012,165(6):1617-1643.
18. YOU HanNing,GAO Ting,Raup-Konsavage W M,et al.Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice[J].Kidney Int,2017,91(3):671-682.
19. de Zeeuw D,Bekker P,Henkel E,et al.The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial[J].Lancet Diabetes Endocrinol,2015,3(9):687-696.
20. Kanasaki K,Shi S,Kanasaki M,et al.Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen[J].Diabetes,2014,63(6):2120-2131.
21. Tani S,Nagao K,Hirayama A.Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor,vildagliptin: a pilot study[J].Am J Cardiovasc Drugs,2013,13(6):443-450.
22. Groop P H,Cooper M E,Perkovic V,et al.Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction[J].Diabetes Care,2013,36(11):3460-3468.
23. Fang L,Radovits T,Szabó G,et al.Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3′,5′ guanosine monophosphate (cGMP) level in podocytes[J].Nephrol Dial Transplant,2013,28(7):1751-1761.
24. Jeong K H,Lee T W,Ihm C G,et al.Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats[J].Am J Nephrol,2009,29(3):274-282.
25. Scheele W,Diamond S,Gale J,et al.phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy[J].J Am Soc Nephrol,2016,27(11):3459-3468.
26. Gill P S,Wilcox C S.NADPH oxidases in the kidney[J].Antioxid Redox Signal,2006,8(9-10):1597-1607.
27. Gorin Y,Cavaglieri R C,Khazim K,et al.Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes[J].Am J Physiol Renal Physiol,2015,308(11):F1276-F1287.
28. Cha J J,Min H S,Kim K T,et al.APX-115,a first-in-class pan-NADPH oxidase (Nox) inhibitor,protects db/db mice from renal injury[J].Lab Invest,2017,97(4):419-431.
29. O’Sullivan L A,Liongue C,Lewis R S,et al.Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease[J].Mol Immunol,2007,44(10):2497-2506.
30. ZHANG HongYu,Nair V,Saha J,et al.Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice[J].Kidney Int,2017,92(4):909-921.
31. Berthier C C,ZHANG HongYu,Schin M,et al.Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy[J].Diabetes,2009,58(2):469-477.